POXEL |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.706 EUR | +6.97% |
|
+8.10% | +28.31% |
| Apr. 11 | Poxel: CDC falls below the 10% threshold | CF |
| Feb. 15 | Poxel S.A. Reports Unaudited Revenue Results for the Fourth Quarter and Full Year Ended December 31, 2023 | CI |
| Sales 2021 | 13.4M 14.39M | Sales 2022 | 674K 724K | Capitalization | 27.16M 29.17M |
|---|---|---|---|---|---|
| Net income 2021 | -23M -24.7M | Net income 2022 | -31M -33.29M | EV / Sales 2021 | 10.7 x |
| Net Debt 2021 | 3M 3.23M | Net Debt 2022 | 32.74M 35.16M | EV / Sales 2022 | 88.9 x |
| P/E ratio 2021 |
-5.92
x | P/E ratio 2022 |
-0.87
x | Employees | 15 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 99.57% |
More Fundamentals
* Assessed data
More news
Latest transcript on Poxel
More press releases
| 1 day | +1.06% | ||
| 1 week | +1.99% | ||
| Current month | +28.76% | ||
| 1 month | +33.40% | ||
| 3 months | +39.98% | ||
| 6 months | +88.42% | ||
| Current year | +21.05% |
1 week
0.64
0.90
1 month
0.490.90
Current year
0.360.90
1 year
0.300.95
3 years
0.307.75
5 years
0.3013.80
10 years
0.3017.74
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 61 | 09-03-05 | |
Sebastien Bolze
FOU | Founder | - | 09-03-05 |
| Founder | - | 09-03-05 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Richard Kender
BRD | Director/Board Member | 68 | 15-03-11 |
Pascale Boissel
BRD | Director/Board Member | 57 | 15-03-04 |
Thomas Kuhn
FOU | Founder | 50 | 09-03-05 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 0.706 | +6.97% | 360 794 |
| 24-04-25 | 0.66 | -12.47% | 692,760 |
| 24-04-24 | 0.754 | -2.08% | 799,122 |
| 24-04-23 | 0.77 | -2.65% | 975,745 |
| 24-04-22 | 0.791 | +20.95% | 917,394 |
Real-time Euronext Paris, April 26, 2024 at 04:19 am EDT
More quotes
Poxel is a biopharmaceutical company specializing in developing innovative treatments for metabolic diseases, including non-alcoholic steatohepatitis (NASH) and rare diseases.
TWYMEEG® (Imeglimine), Poxel's lead product and the first in its class of medicines, which targets mitochondrial dysfunction, has been marketed in Japan for the treatment of type 2 diabetes.
For the treatment of NASH, the PXL065 met its primary endpoint in a streamlined Phase II trial, and PXL770 has completed a Phase IIa proof-of-concept study by reaching its objectives. In adrenoleukodystrophy (ALD), a rare inherited metabolic disease, the company intends to initiate Phase IIa proof-of-concept studies with the PXL065 and the PXL770 in patients with adrenomyeloneuropathy (AMN).
Calendar
2024-05-15
- Q1 2024 Sales and Revenue Release
| 1st Jan change | Capi. | |
|---|---|---|
| +21.05% | 27.4M | |
| -2.26% | 103B | |
| +1.41% | 95.71B | |
| +0.93% | 22.02B | |
| -17.84% | 20.9B | |
| -9.68% | 17.85B | |
| -42.83% | 16.21B | |
| -17.63% | 15.52B | |
| +4.55% | 13.86B | |
| +32.11% | 12.04B |
- Stock Market
- Equities
- POXEL Stock
